Unless you're a medical expert, you'll probably never have heard of ISIS Pharmaceuticals. But in five to ten years' time, assuming things go according to plan, this biotech outfit could be a household name. That's because it has developed a ground-breaking new technique called 'antisense'.
Many of today's most common diseases such as cardiovascular problems, cancer and diabetes are caused by 'bad' proteins being wrongly produced in the human body. Current drugs attack these dangerous cells, but the problem is that the side effects can be extreme, and the efficacy poor.
In contrast, antisense operates one step ahead in the DNA chain. It stops these disease-causing proteins from ever being generated by turning off the genes that encode the protein. This means none of the 'good' cells are harmed, so the side effects are far fewer, and the treatment can be tailored to each individual patient.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
ISIS owns 1,600 patents and currently has 19 drugs in the pipeline, most of which are being jointly developed with partners such as Genzyme, Bristol-Myers Squibb and Novartis.
ISIS Pharmaceuticals (Nasdaq: ISIS)
ISIS's first potential blockbuster drug is Mipomersen, which is aimed at cutting cholesterol levels. It's presently undergoing Phase III clinical trials; submission to the US regulator, the FDA, is set for 2010. So far the results have been very encouraging. The chief executive said in August that "key opinion leaders with whom we have shared the detailed data are thrilled".
Assuming he's right, and the FDA approves Mipomersen in 2011, shares could rocket overnight. A positive verdict would not only give the green light to this specific treatment, but would more importantly provide a huge endorsement to the whole antisense drug class. There's also no danger of patent expiries until 2023 at the earliest, and the group has $500m in net cash (or $5 a share) to fund itself for the foreseeable future.
What are the potential pitfalls? As with most early-stage biotechs, ISIS is still loss making and its success depends on one main therapeutic area. But with antisense being such a breakthrough, ISIS looks a good bet on the long-term growth in personalised medicine and ageing populations, along with being a takeover target for Big Pharma.
Recommendation: speculative BUY at $14.50 (market capitalisation $1.4bn)
Paul Hill also writes a weekly share-tipping newsletter, Precision Guided Investments
Paul gained a degree in electrical engineering and went on to qualify as a chartered management accountant. He has extensive corporate finance and investment experience and is a member of the Securities Institute.
Over the past 16 years Paul has held top-level financial management and M&A roles for blue-chip companies such as O2, GKN and Unilever. He is now director of his own capital investment and consultancy firm, PMH Capital Limited.
Paul is an expert at analysing companies in new, fast-growing markets, and is an extremely shrewd stock-picker.
Equity release rates drop – is it worth unlocking cash from your home?
News Lifetime mortgage rates are falling from their record highs - is equity release worth another look?
By Marc Shoffman Published
Hargreaves Lansdown launches fixed-term cash ISA product
savings/hargreaves-lansdown-fixed-cash-isa-launch Investment platform Hargreaves Lansdown is to offer fixed term cash ISAs via its Active Savings platform paying 4.8%, tax free - but is it any good?
By Kalpana Fitzpatrick Published